Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Glaxo Wellcome Retrovir

Executive Summary

Glaxo Wellcome Retrovir: 300 mg tablet formulation of zidovudine launched the week of Oct. 21. The 300 mg tablet, approved Oct. 4 by FDA, is intended to simplify combination with Glaxo's Epivir (3TC, lamivudine) to allow for twice-daily dosing of 150 mg Epivir plus 300 mg Retrovir; previously, patients took Epivir twice daily but two 100 mg Retrovir capsules three times daily. A dose frequency study found no safety or efficacy differences between the formulations, according to labeling. Price to wholesalers will be $3.98 per tablet for 300 mg form; 100 mg tabs cost $1.59 each AWP...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS029076

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel